These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 12087353)

  • 21. Low rate of bleeding and thrombotic complications of oral anticoagulant therapy independent of age in the real-practice of an anticoagulation clinic.
    Poli D; Antonucci E; Lombardi A; Boddi V; Gensini GF; Abbate R; Prisco D
    Blood Coagul Fibrinolysis; 2003 Apr; 14(3):269-75. PubMed ID: 12695750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon.
    van Geest-Daalderop JH; Hutten BA; Péquériaux NC; de Vries-Goldschmeding HJ; Räkers E; Levi M
    Thromb Haemost; 2007 Oct; 98(4):747-55. PubMed ID: 17938797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants.
    Penning-van Beest FJ; Koerselman J; Herings RM
    J Thromb Haemost; 2008 Feb; 6(2):284-90. PubMed ID: 18031295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risks of oral anticoagulant therapy with increasing age.
    Torn M; Bollen WL; van der Meer FJ; van der Wall EE; Rosendaal FR
    Arch Intern Med; 2005 Jul; 165(13):1527-32. PubMed ID: 16009869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment.
    Pengo V; Barbero F; Biasiolo A; Pegoraro C; Cucchini U; Iliceto S
    Am J Clin Pathol; 2003 Dec; 120(6):944-7. PubMed ID: 14671984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction.
    Schalekamp T; van Geest-Daalderop JH; Kramer MH; van Holten-Verzantvoort AT; de Boer A
    Eur J Clin Pharmacol; 2007 Apr; 63(4):335-43. PubMed ID: 17318526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.
    Lindh JD; Lundgren S; Holm L; Alfredsson L; Rane A
    Clin Pharmacol Ther; 2005 Nov; 78(5):540-50. PubMed ID: 16321620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
    Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subclinical hyperthyroidism seems not to have a significant impact on systemic anticoagulation in patients with coumarin therapy.
    Bucerius J; Naubereit A; Joe AY; Ezziddin S; Biermann K; Risse J; Palmedo H; Oldenburg J; Biersack HJ
    Thromb Haemost; 2008 Nov; 100(5):803-9. PubMed ID: 18989524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements.
    van Geest-Daalderop JH; Péquériaux NC; van den Besselaar AM
    Thromb Haemost; 2009 Sep; 102(3):588-92. PubMed ID: 19718481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
    Gschwind L; Rollason V; Boehlen F; Rebsamen M; Combescure C; Grünenwald M; Matthey A; Bonnabry P; Dayer P; Desmeules JA
    Pharmacogenomics; 2013 May; 14(7):745-53. PubMed ID: 23651023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
    Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
    Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.
    Pérez-Gómez F; Alegría E; Berjón J; Iriarte JA; Zumalde J; Salvador A; Mataix L;
    J Am Coll Cardiol; 2004 Oct; 44(8):1557-66. PubMed ID: 15489085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The necessity to assess anticoagulation status in elderly injured patients.
    Williams TM; Sadjadi J; Harken AH; Victorino GP
    J Trauma; 2008 Oct; 65(4):772-6; discussion 776-7. PubMed ID: 18849789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risks factors for highly unstable response to oral anticoagulation: a case-control study.
    Palareti G; Legnani C; Guazzaloca G; Lelia V; Cosmi B; Lunghi B; Marchetti G; Poli D; Pengo V;
    Br J Haematol; 2005 Apr; 129(1):72-8. PubMed ID: 15801958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overanticoagulation is associated with renal function decline.
    van Blijderveen JC; Verhamme KM; Zietse R; Visser LE; Romio SA; Buhre PN; Sturkenboom MC; Hofman A; Straus SM; Stricker BH
    J Nephrol; 2013; 26(4):691-8. PubMed ID: 23843045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
    Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
    Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism.
    Torn M; van der Meer FJ; Rosendaal FR
    Arch Intern Med; 2004 Mar; 164(6):668-73. PubMed ID: 15037497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.